C-Reactive Protein

Lipid oxidation rate — an indicator of “metabolic flexibility” — may be greater among women with normal weight vs. women with overweight or obesity during pregnancy, according to findings published in Metabolism. In addition, insulin resistance and inflammation may be influenced by this flexibility.

The Healio Pulmonology Editors have compiled a list of updates in chronic obstructive pulmonary disease from 2019.

PHILADELPHIA — Rilonacept in patients with recurrent pericarditis led to improvements in clinical and patient-reported measures as soon as after the first injection, according to data presented at the American Heart Association Scientific Sessions.

A machine learning program with clinical and coronary CT angiography data identified the top predictors of noncalcified coronary burden in psoriasis, which were markers related to obesity, dyslipidemia and inflammation, according to research in Journal of the American Academy of Dermatology.

PHILADELPHIA — Acute preprocedural administration of colchicine did not reduce PCI-related myocardial injury or MACE compared with placebo, but attenuation of the inflammatory response was observed in the COLCHICINE-PCI trial, which was presented at the American Heart Association Scientific Sessions.

WASHINGTON — Data presented here from the ROCKIES phase 3 trial showed use of the investigational hypoxia-inducible factor prolyl hydroxylase inhibitor drug roxadustat led to greater increases in hemoglobin levels compared to use of epoetin alfa in patients with ESKD and anemia.

CHICAGO — Updated guidelines provide clear CVD prevention strategies for most patients, but barriers to optimal treatment in some patients remain, including issues related to sex, age, inflammation and adequate testing, according to a speaker.

PARIS — In the first randomized trial designed to assess a PCSK9 inhibitor in patients with high-risk ACS, the addition of evolocumab to statin therapy was well tolerated and substantially reduced LDL levels, with a majority of patients within currently recommended target levels following treatment.

Around two-thirds of patients in a 5-year, multisite study who survived hospitalization for sepsis demonstrated persistent elevated levels of inflammation and immunosuppression biomarkers for up to 1 year, placing them at risk for worse long-term outcomes, including death or readmission, researchers found.